The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Glioblastoma Multiforme Therapy and Mechanisms of Resistance
Open accessAbstract
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12–14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Researchers are currently pursuing compounds that normalize tumor vasculature to disrupt tumor growth and enhance drug delivery [95].”
BackgroundCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
A restricted cell population propagates glioblastoma growth after chemotherapy
Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,354
Mathew, R., Karantza-Wadsworth, V., & White, E. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2254 · Cited by 1,798
Shen, Q., Wang, Y., Kokovay, E., Lin, G., Chuang, S.-M., Goderie, S. K., Roysam, B., & Temple, S. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.07.026 · Cited by 1,027
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938 · cited 1×
“For example, 30%–40% of GBM tumors have amplification of the epidermal growth factor receptor (EGFR), a tyrosine kinase receptor that activates MAPK and PI3K signaling [3].”
BackgroundGlioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth
Cheng, L., Huang, Z., Zhou, W., Wu, Q., Donnola, S., Liu, J. K., Fang, X., Sloan, A. E., Mao, Y., Lathia, J. D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.02.021 · Cited by 905 · cited 1×
“Lastly, recent data suggests that GBM stem cells further contribute to tumor vascularization by differentiating into pericytes, the cells that wrap around endothelial cells to support and maintain them [74,75].”
BackgroundRepair of O6-alkylguanine by alkyltransferases
Pegg, A. E. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00017-x · Cited by 576 · cited 2×
“O6-BG is a small-molecule pseudosubstrate that transfers a benzyl group to the MGMT active site cysteine 145 residue, thereby, inactivating MGMT and preventing removal of methyl groups from the DNA [26].”
BackgroundDirect In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem Cells
Lathia, J. D., Gallagher, J., Myers, J. T., Li, M., Vasanji, A., McLendon, R. E., Hjelmeland, A. B., Huang, A. Y., & Rich, J. N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024807 · Cited by 158
Cited by
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Stepanenko, A. A., & Dmitrenko, V. V. (2015) · Gene · doi:10.1016/j.gene.2015.08.009 · Cited by 315
Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives
Seker-Polat, F., Pinarbasi Degirmenci, N., Solaroglu, I., & Bagci-Onder, T. (2022) · Cancers · doi:10.3390/cancers14020443 · Cited by 253
Mrugala, M. M., Engelhard, H. H., Dinh Tran, D., Kew, Y., Cavaliere, R., Villano, J. L., Annenelie Bota, D., Rudnick, J., Love Sumrall, A., Zhu, J.-J., et al. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.010 · Cited by 152
“The shorter survival in patients treated previously with bevacizumab may be a result of acquired tumor resistance and development of a more aggressive phenotype with infiltrative tumor progression on MRI.(9,10) Moreover, patients with recurrent GBM tumors that progress while on bevacizumab therapy are typically resist…”
BackgroundInfluentialPotent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
Her, N.-G., Oh, J.-W., Oh, Y. J., Han, S., Cho, H. J., Lee, Y., Ryu, G. H., & Nam, D.-H. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0825-1 · Cited by 68
Metadata
- Authors
- Ramirez, Y., Weatherbee, J., Wheelhouse, R., & Ross, A.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2013-11-25
- Volume
- 6
- Issue
- 12
- Pages
- 1475-1506
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W2099418348
- Cited by
- 236
- References
- 12
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.